Pereira MJ, et al. - Among adults with obesity and without diabetes, researchers performed post hoc analysis investigating the metabolic effects and baseline associations with bodyweight loss on coadministration of dapagliflozin and exenatide once weekly (QW). They randomized the participants to double-blind oral dapagliflozin 10 mg (DAPA) once daily plus subcutaneous long-acting exenatide 2 mg QW (ExQW) or placebo over 24 weeks, followed by an open-label extension from 24–52 weeks during which all participants received active treatment. During the oral glucose tolerance test (OGTT), less free fatty acid (FFA) suppression was noted with DAPA+ExQW vs placebo. This indicates compensatory lipid mobilization for energy production when glucose availability was reduced because of glucosuria. With DAPA+ExQW coadministration, the expected increase in glucagon with DAPA did not occur. The SNP variant rs10010131 A allele, lower baseline adiposity (BMI), and lower baseline insulin secretion (IGI) were noted in association with bodyweight loss with DAPA+ExQW.